← Back to Newsroom

Furnetics Unlimited Ltd. today confirms that the corporation has, on the ninth of June, provided the secretariat of the World Health Organization Access to COVID-19 Tools (ACT) Accelerator with an unsolicited private technical brief on comparative characteristics of somatic-delivery vector platforms, drawn from the internal characterisation library maintained by the Hephaestus Group since its 1993 constitution. The brief is a reference document. It proposes no Furnetics product, offers no Furnetics platform for scale-up, and takes no position, public or private, on the relative merits of any candidate vaccine under consideration by the Accelerator or by any of its member bodies.

The submission was made in response to no specific solicitation and was reviewed prior to release by the corporation's Independent Ethics Board under the standing procedure for third-party disclosures of research-adjacent material. The Board recorded no objection. The corporation has been given no assurance that the material will be circulated, cited, or acted upon by the secretariat or by any body of the Accelerator; the corporation neither expects nor requests any such assurance, and will decline any invitation, subsequent to release, to expand the brief into an advisory role.

What the brief contains

The document, thirty-nine pages including appendices, sets out comparative technical characteristics of the recombinant delivery-vector families the Hephaestus Group has characterised in the course of its own preclinical and clinical-manufacturing work over the twenty-seven years since. The areas covered are those on which the Group's own internal register carries longitudinal data and which the Board considered appropriate for release in platform-comparative rather than subject-derived form:

• Comparative serotype tropism. Tissue-target and receptor-affinity notes across the Group's AAV serotype library, maintained since 1997, with annotations on cross-reactivity, off-target uptake, and the durability of tropism under manufacturing pressure.
• Cargo capacity against induced immunogenicity. Trade-off curves across adeno-associated, adenoviral (E1-deleted and helper-dependent), non-integrating lentiviral pseudotypes, and self-amplifying nucleic-acid platforms, at insert lengths and dose ranges relevant to prophylactic indications.
• Persistence and clearance kinetics. Comparative in-vivo persistence and clearance in adult, immunocompetent recipients, drawn from the Group's post-procedure structured-follow-up register and restated in platform-neutral form.
• Manufacturing yield at emergency-response scale. Cell-line yield curves for clinical-grade material at unit ranges eight to nine orders of magnitude above the Group's steady-state, with commentary on the limits of extrapolation from small-batch data.
• Pre-existing anti-vector immunity. Regional prevalence notes for pre-existing neutralising immunity in unselected adult populations, drawn from the Group's own donor-panel surveys and cross-referenced against the published epidemiological literature.
• Cold-chain envelope. Storage, distribution, and last-mile temperature-stability requirements for each family, expressed in the WHO's own Performance, Quality and Safety (PQS) categorisation to avoid the introduction of a private taxonomy.

Absent from the brief are: any Furnetics product; any Furnetics platform offer; any characterisation of the ongoing candidate-vaccine pipeline; and any opinion, favourable or otherwise, on any specific vaccine platform under consideration by the Accelerator or the wider international response. The corporation has taken and will take no public position on the merits of the candidate vaccines. It does not consider itself a competent commentator on emergency prophylaxis and does not intend to become one.

Why this material and why now

The Hephaestus Group's comparative delivery-vector library is, in the corporation's estimation, the largest continuous private characterisation programme of its kind maintained outside a small number of national laboratories. It is not a proprietary asset in the ordinary commercial sense — the Group maintains it because its own somatic-modification work requires it — and the Group's founding convention has always been to publish no work whose disclosure would embarrass its subjects. Platform-comparative material is not subject-derived. The Independent Ethics Board has, on several occasions since its 2014 constitution, discussed the conditions under which such material might responsibly be made available to public-health bodies. The Board has concluded, in its second-quarter minute of the current year, that those conditions are met by the present circumstance, and by this circumstance alone.

“Comparative delivery-vector characterisation is old work, done over long horizons, and it does not date quickly. Ours has been done in the course of a very particular sort of clinical practice, and it is not the practice the Accelerator is engaged in. That does not mean the record has nothing to offer. We have offered it, on those terms and no other, and we will now return to our own bench.”

— Dr. Ines Marchetti-Roux, Chief Scientific Officer

What is not being offered

Furnetics is not offering the Accelerator, or any member body, the use of its own manufacturing capacity. Furnetics is not offering to enter, and will not enter, the field of emergency infectious-disease prophylaxis.

Media enquiries relating to the brief may be directed to the Office of the General Counsel at 15 Sükhbaatar Square, Ulaanbaatar. Furnetics will not release the text of the brief; enquiries relating to its content, or to any conclusions the secretariat or any member body may draw from it, should be directed to the World Health Organization in the ordinary way, and Furnetics will not answer such enquiries on the secretariat's behalf.

— ends —